Oncotelic Therapeutics Investigates OT-101 for Pediatric Brain Tumors

Oncotelic Therapeutics Inc. is advancing the development of OT-101, an immunotherapy drug, for the treatment of diffuse midline glioma (DMG), a rare and aggressive pediatric brain tumor. Data and a clinical trial design for the drug's use in DMG were presented at a scientific meeting.

The research suggests OT-101 could offer a new therapeutic approach for DMG. The drug is designed to inhibit the production of the protein TGF-β2. Cancer cells often utilize TGF-β2 to evade the host immune response. OT-101 aims to dismantle this immune cloak, allowing the immune system to target cancer cells.

Preclinical studies have indicated that OT-101 can cross the blood-brain barrier and perfuse the brain, including midline structures, depending on the administration method. Safety studies have supported the drug's use for intraventricular administration.

Analyses of patient data have shown that high expression of TGF-β2 is associated with poorer outcomes in various glioma types. While OT-101 has previously shown activity in pancreatic cancer, melanoma, and glioblastoma, its specific potential in DMG is now under investigation.

Oncotelic Therapeutics is planning a Phase 2 clinical trial to investigate OT-101 for DMG patients. The trial will involve administering the drug via an Ommaya reservoir following radiation therapy.